News & Updates
Filter by Specialty:
Updated long-term data AUGMENT R2 efficacy for R/R iNHL
In the longer-term follow-up of the phase III AUGMENT trial, the lenalidomide-rituximab (R2) combination trumped the rituximab-placebo regimen (control) for the treatment of relapsed/refractory indolent non-Hodgkin lymphoma (R/R iNHL).
Updated long-term data AUGMENT R2 efficacy for R/R iNHL
22 Dec 2022
No excess pancreatic cancer risk with dihydropyridine calcium channel blockers, study says
Exposure to dihydropyridine calcium channel blockers does not appear to put patients at increased risk of developing pancreatic cancer as compared with thiazide diuretics, as shown in a large study.
No excess pancreatic cancer risk with dihydropyridine calcium channel blockers, study says
22 Dec 2022
Local data support continuation of RASIs in patients with T2D and advanced CKD
Discontinuation of renin-angiotensin system inhibitors (RASIs) is associated with higher risks of cardiorenal complications and neutral risk of all-cause mortality in patients with type 2 diabetes (T2D) and advanced chronic kidney disease (CKD), according to researchers from the Chinese University of Hong Kong (CUHK).
Local data support continuation of RASIs in patients with T2D and advanced CKD
22 Dec 2022
IBD study to shed light on how gut microbiota in pregnancy affects offspring
Researchers at the Chinese University of Hong Kong (CUHK) are recruiting pregnant women with inflammatory bowel disease (IBD), their newborns and spouse for a study to investigate how early-life exposure influences gut microbiota and IBD risk in the offspring, and to develop novel treatments for the increasingly prevalent condition.
IBD study to shed light on how gut microbiota in pregnancy affects offspring
22 Dec 2022
HF meds rapid up-titration reduces readmission, mortality after acute HF hospitalization
Rapidly maximizing medications in patients discharged from hospital following acute heart failure (AHF) reduced the risk of hospital readmission or death at 180 days, according to results of the STRONG-HF* trial presented at AHA 2022.
HF meds rapid up-titration reduces readmission, mortality after acute HF hospitalization
21 Dec 2022
5-fraction SBRT improves outcomes in osseous renal cell carcinoma metastases
Local-control outcomes are encouraging in patients with osseous renal cell carcinoma metastases who went through five fractions of stereotactic body radiotherapy (SBRT), reports a study.
5-fraction SBRT improves outcomes in osseous renal cell carcinoma metastases
21 Dec 2022
Female, male infertility: Adherence to anti-inflammatory diets may bring new babies
Anti-inflammatory dietary patterns, such as the Mediterranean diet, may improve the chances of conception among couples who struggle with infertility, according to a recent review.
Female, male infertility: Adherence to anti-inflammatory diets may bring new babies
21 Dec 2022
Obesity associated with adverse ITP outcomes
In a study presented at ASH 2022, obesity was found to be associated with adverse outcomes in individuals with primary immune thrombocytopenia (ITP; formerly known as thrombocytopenia purpura).
